Cite

HARVARD Citation

    Norrby, M. et al. (2017). Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine. 35 (12), pp. 1652-1661. [Online]. 
  
Back to record